By Fineline Cube 
Prellis Biologics, Inc. and global biopharma leader Eli Lilly & Co. (NYSE: LLY) today announced a multi‑target drug discovery partnership. The collaboration will harness Prellis’ proprietary EXIS and AntiGen AI platforms to accelerate the identification of highly diverse, fully human antibodies across a portfolio of disease targets.
How the Collaboration Works
| Component | What It Brings |
|---|---|
| EXIS & AntiGen AI | Machine‑learning algorithms that rapidly evaluate antibody affinity, specificity, and developability, shortening the lead‑optimization cycle. |
| Lymph Node Organoids | Prellis’ engineered organoid system that mimics the human immune microenvironment, enabling physiologically relevant screening of antibody candidates. |
| Joint Discovery & Development | Prellis and Lilly will co‑discover, develop, and potentially commercialize antibodies for pre‑selected targets, sharing technical expertise and resources. |
Financial & Commercial Terms
- Upfront Payment – Prellis receives a cash infusion upon signing.
- Milestone & Royalty Structure – Subsequent development, regulatory approval, and sales milestones trigger payments to Prellis, with ongoing royalties on commercial products.
Strategic Rationale
- Speed to Market – Combining organoid biology with AI optimization is expected to cut discovery timelines by 30‑40 % compared with conventional pipelines.
- Portfolio Diversification – Eli Lilly gains access to a library of novel, fully human antibodies that could fill unmet needs in oncology, immunology, and rare diseases.
- Innovation Leadership – The partnership positions both companies at the forefront of next‑generation antibody therapeutics, reinforcing their commitment to precision medicine.-Fineline Info & Tech